In the weeks and months after the novel coronavirus emerged, Calibr at Scripps Research transformed into an international hub for COVID-19 drug discovery. In this Front Row lecture, Arnab Chatterjee, PhD, shares how Calibr scientists and their many collaborators are leveraging a unique resource—the ReFRAME drug repurposing collection—to help identify safe antiviral drugs that can be rapidly advanced to patients. Learn why Calibr was especially well poised to meet the COVID

Presented: May 6, 2020